UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (675) 675
science & technology (644) 644
life sciences & biomedicine (613) 613
male (427) 427
female (402) 402
middle aged (285) 285
oximes - adverse effects (273) 273
adult (253) 253
oximes - therapeutic use (247) 247
oximes (245) 245
animals (231) 231
biological and medical sciences (214) 214
medical sciences (207) 207
aged (194) 194
melanoma - drug therapy (183) 183
oximes - administration & dosage (180) 180
oximes - pharmacology (143) 143
pharmacology & pharmacy (143) 143
imidazoles - adverse effects (142) 142
melanoma (139) 139
proto-oncogene proteins b-raf - antagonists & inhibitors (126) 126
proto-oncogene proteins b-raf - genetics (117) 117
dermatology (115) 115
skin neoplasms - drug therapy (114) 114
toxicology (108) 108
imidazoles - administration & dosage (107) 107
oncology (99) 99
mutation (96) 96
imidazoles - therapeutic use (91) 91
pyridones - administration & dosage (81) 81
pyrimidinones - administration & dosage (81) 81
treatment outcome (81) 81
rats (80) 80
melanoma - genetics (79) 79
pyridones - adverse effects (78) 78
pyrimidinones - adverse effects (78) 78
technetium tc 99m exametazime (78) 78
skin neoplasms - pathology (77) 77
abridged index medicus (72) 72
adolescent (71) 71
organotechnetium compounds (70) 70
antineoplastic agents - adverse effects (69) 69
dabrafenib (69) 69
antineoplastic combined chemotherapy protocols - adverse effects (68) 68
pharmacology. drug treatments (68) 68
melanoma - pathology (67) 67
dose-response relationship, drug (65) 65
antineoplastic combined chemotherapy protocols - therapeutic use (64) 64
protein kinase inhibitors - adverse effects (64) 64
mice (63) 63
aged, 80 and over (61) 61
care and treatment (61) 61
double-blind method (61) 61
antineoplastic agents - therapeutic use (59) 59
time factors (56) 56
clinical trials as topic (54) 54
metastasis (53) 53
analysis (51) 51
melanoma - secondary (49) 49
research (49) 49
indoles - adverse effects (48) 48
oximes - chemistry (48) 48
sulfonamides - adverse effects (48) 48
fluvoxamine (46) 46
norgestrel - analogs & derivatives (46) 46
organophosphate poisoning (45) 45
risk factors (45) 45
poisoning (44) 44
acetylcholinesterase (43) 43
protein kinase inhibitors - therapeutic use (43) 43
skin neoplasms - genetics (43) 43
young adult (43) 43
drug therapy (42) 42
indoles - therapeutic use (42) 42
oximes - pharmacokinetics (42) 42
administration, oral (41) 41
physical sciences (41) 41
tomography, emission-computed, single-photon (41) 41
cancer (40) 40
health aspects (40) 40
neurosciences & neurology (40) 40
sulfonamides - therapeutic use (40) 40
cardiovascular system & cardiology (39) 39
chemistry (39) 39
general & internal medicine (39) 39
atropine (38) 38
oxime (38) 38
radionuclide imaging (38) 38
vemurafenib (38) 38
drug therapy, combination (37) 37
toxicity (37) 37
antidepressive agents - adverse effects (36) 36
protein kinase inhibitors - administration & dosage (36) 36
trametinib (36) 36
biochemistry & molecular biology (35) 35
medicine, general & internal (35) 35
pyridones - therapeutic use (35) 35
pyrimidinones - therapeutic use (35) 35
acetylcholinesterase - metabolism (33) 33
chemical and industrial products toxicology. toxic occupational diseases (33) 33
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (875) 875
French (15) 15
German (11) 11
Japanese (7) 7
Italian (3) 3
Polish (3) 3
Spanish (2) 2
Bulgarian (1) 1
Czech (1) 1
Danish (1) 1
Finnish (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The oncologist (Dayton, Ohio), ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 823 - 833
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | Life Sciences & Biomedicine | Oncology | Science & Technology | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Index Medicus | Melanoma and Cutaneous Malignancies
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 1, pp. 30 - 39
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 19, pp. 1813 - 1823
Journal Article
The New England journal of medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 18, pp. 1694 - 1703
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Tumors of the skin and soft tissue. Premalignant lesions | Biological and medical sciences | General aspects | Medical sciences | Dermatology | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Imidazoles - pharmacokinetics | Fever - chemically induced | Drug Therapy, Combination - adverse effects | Melanoma - genetics | Adult | Female | Imidazoles - therapeutic use | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | MAP Kinase Signaling System - drug effects | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyridones - therapeutic use | Mutation | Pyridones - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Melanoma | Product/Service Evaluations | Research | Antineoplastic agents | Antimitotic agents | Gene mutations | Causes of | Genetic aspects | Dosage and administration | Drug therapy, Combination | Drug therapy | Cell survival | Protein kinase | Skin diseases | MAP kinase | Kinases | Patients | Drug dosages | Fever | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 08/2019, Volume 381, Issue 7, pp. 626 - 636
Journal Article
Annals of oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1631 - 1639
Journal Article
Journal Article
Annals of oncology, ISSN 0923-7534, 06/2015, Volume 26, Issue 6, pp. 1238 - 1244
Journal Article